Hypothyroidism due to iodide transport defect

Summary

Hypothyroidism due to iodide transport defect (MONDO:0043103) is a disease. A subtype of congenital hypothyroidism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hypothyroidism due to iodide transport defect
Mondo ID	MONDO:0043103
NCIT	C121747
SNOMED CT	22558005
UMLS	C0271826
MedGen	124412
GARD	0002938
Is cancer (heuristic)	no

Also known as: hypothyroidism due to iodide transport defect · iodide Transport defect · iodide transport defect

Disease family

This is a subtype of congenital hypothyroidism. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › thyroid gland disorder › hypothyroidism › congenital hypothyroidism › hypothyroidism due to iodide transport defect

Related subtypes (7): hypothyroidism, congenital, nongoitrous, familial thyroid dyshormonogenesis, Pendred syndrome, transient congenital hypothyroidism, permanent congenital hypothyroidism, idiopathic congenital hypothyroidism, Kocher-debre-Semelaigne syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.